The European Commission (EC) granted marketing authorization for Biogen Inc.’s Vumerity (diroximel fumarate) to treat adults with relapsing-remitting multiple sclerosis (MS).
The U.S. Food and Drug Administration approved Biogen Inc.’s new intramuscular injection route of administration for Plegridy (peginterferon beta-1a) for the treatment of relapsing forms of multiple sclerosis.
New York-based Immunic reported positive topline data from the company’s Phase II EMPhASIS trial of IMU-838 in relapsing-remitting multiple sclerosis (RRMS).
Researchers with City University of New York and the Icahn School of Medicine at Mount Sinai identified specific biological differences between relapsing-remitting MS (RRMS) – in which patients often go into clinical remission – and progression MS, which has the potential to lead to new therapeutic approaches and diagnostic testing.
Novartis announced the full data of the ASSESS study, which evaluated the efficacy of oral, once-daily Gilenya (fingolimod) at 0.5mg and 0.25mg versus once-daily subcutaneous injections of glatiramer acetate 20mg in reducing disease activity over 12 months in patients with relapsing remitting multiple sclerosis (RRMS).
EMD Serono, a unit of Merck KGaA, announced that the U.S. FDA approved Mavenclad (cladribine) for adults with relapsing-remitting multiple sclerosis and active secondary progressive disease.
Roche company Genentech has released data from a long-term clinical trial of Ocrevus (ocrelizumab) in multiple sclerosis. The U.S. FDA and the European Medicines Agency accepted Novartis’ marketing applications for siponimod (BAF312) to treat secondary-progressive multiple sclerosis in adults.
Roche faces a fresh row over drug pricing in Britain, following a decision by the body responsible for medicine use within the state health service not to approve the company’s drug Ocrevus for treating a highly disabling form of multiple sclerosis (MS).
Active Biotech regained the global development and commercialization rights to the neurodegenerative disease drug laquinimod from Teva Pharmaceutical Industries.
Merck KGaA won a key recommendation to become an entrant to the oral MS drug market in Europe, six years after its first attempt to launch the cladribine pill failed.